Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey
Published by Oxford University Press for the Infectious Diseases Society of America 2020..
We compared severe acute respiratory syndrome coronavirus 2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April and May 2020 and found these 2 estimates to be similar (4.94% vs 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence.
| Errataetall: |
CommentIn: Clin Infect Dis. 2021 Nov 2;73(9):e3124-e3126. - PMID 33338219 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 9 vom: 02. Nov., Seite e3120-e3123 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bajema, Kristina L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.11.2021 Date Revised 08.11.2021 published: Print CommentIn: Clin Infect Dis. 2021 Nov 2;73(9):e3124-e3126. - PMID 33338219 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa1804 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318659824 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318659824 | ||
| 003 | DE-627 | ||
| 005 | 20231225165820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa1804 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318659824 | ||
| 035 | |a (NLM)33300579 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bajema, Kristina L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2021 | ||
| 500 | |a Date Revised 08.11.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Clin Infect Dis. 2021 Nov 2;73(9):e3124-e3126. - PMID 33338219 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Oxford University Press for the Infectious Diseases Society of America 2020. | ||
| 520 | |a We compared severe acute respiratory syndrome coronavirus 2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April and May 2020 and found these 2 estimates to be similar (4.94% vs 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a convenience sampling | |
| 650 | 4 | |a coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a seroprevalence | |
| 650 | 4 | |a severe acute respiratory syndrome–related coronavirus 2 (SARS-CoV-2) | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Dahlgren, F Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Travis W |e verfasserin |4 aut | |
| 700 | 1 | |a Bestul, Nicolette |e verfasserin |4 aut | |
| 700 | 1 | |a Biggs, Holly M |e verfasserin |4 aut | |
| 700 | 1 | |a Tate, Jacqueline E |e verfasserin |4 aut | |
| 700 | 1 | |a Owusu, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Szablewski, Christine M |e verfasserin |4 aut | |
| 700 | 1 | |a Drenzek, Cherie |e verfasserin |4 aut | |
| 700 | 1 | |a Drobeniuc, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Semenova, Vera |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Han |e verfasserin |4 aut | |
| 700 | 1 | |a Browning, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Epperson, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Lily T |e verfasserin |4 aut | |
| 700 | 1 | |a Thornburg, Natalie J |e verfasserin |4 aut | |
| 700 | 1 | |a Edens, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Fry, Alicia M |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Aron J |e verfasserin |4 aut | |
| 700 | 1 | |a Schiffer, Jarad |e verfasserin |4 aut | |
| 700 | 1 | |a Havers, Fiona P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 9 vom: 02. Nov., Seite e3120-e3123 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:9 |g day:02 |g month:11 |g pages:e3120-e3123 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa1804 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 9 |b 02 |c 11 |h e3120-e3123 | ||